medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2020-1-59-62medsovet-5536Research ArticleБРОНХОПУЛЬМОНОЛОГИЯ, ЛОРBRONCHOPULMONOLOGY, ENTЗащита при рецидивирующих респираторных инфекциях у детей: можем ли мы сделать больше?Recurrent respiratory infection protection in children: can we do anything more?РедакционнаястатьяEditorialArticle202006032020015962Copyright © Редакционная с., 20202020Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5536

На XIV научно-практической конференции  «Совершенствование  педиатрической  практики: от простого к сложному» была затронута актуальная тема профилактики и лечения рецидивирующих респираторно-вирусных заболеваний  у детей раннего возраста. Этот вопрос максимально полно постаралась осветить профессор  Сусанна Эспозито, сотрудник Детской больницы им. Пьетро Барилла Университета Пармы (Италия).

рецидивирующие респираторные инфекцииrespiratory infection protectionReferencesEsposito et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;(18):198–209.Esposito et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;(18):198–209.Mincham K. et al. Transplacental immune modulation with a bacterial-derived agent protects against allergic airway inflammation. J Clin Invest. 2018. doi: 10.1172/JCI122631.Mincham K. et al. Transplacental immune modulation with a bacterial-derived agent protects against allergic airway inflammation. J Clin Invest. 2018. doi: 10.1172/JCI122631.Dang A.T. et al. OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Scientific Reports. 2017;(7):1–9.Dang A.T. et al. OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Scientific Reports. 2017;(7):1–9.Parola C. et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PloS one. 2013;8(12).Parola C. et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PloS one. 2013;8(12).Pasquali C. et al. Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract. Frontiers in medicine. 2014;(1):41.Pasquali C. et al. Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract. Frontiers in medicine. 2014;(1):41.Jara-Pérez J.V., Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clinical therapeutics. 2000;22(6):748–759.Jara-Pérez J.V., Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clinical therapeutics. 2000;22(6):748–759.Selwyn B. on behalf of the coordinated data group of Bostid researchers. Comparisons among countries: the epidemiology of acute respiratory infections in young children: comparison of findings from several developing countries. Rev Infect Dis. 1990;12(8):870–888.Selwyn B. on behalf of the coordinated data group of Bostid researchers. Comparisons among countries: the epidemiology of acute respiratory infections in young children: comparison of findings from several developing countries. Rev Infect Dis. 1990;12(8):870–888.Cohen A.J. et al. The global burden of disease due to outdoor air pollution. Journal of Toxicology and Environmental Health, Part A. 2005;68(13–14):1301–1307.Cohen A.J. et al. The global burden of disease due to outdoor air pollution. Journal of Toxicology and Environmental Health, Part A. 2005;68(13–14):1301–1307.Gutiérrez-Tarango M.D., Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest. 2001;119(6):1742–1748.Gutiérrez-Tarango M.D., Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest. 2001;119(6):1742–1748.Gomez Barreto D., De la Torre C., Alvarez A. et al. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children. Allergologia et immunopatho­ logia. 1998;26(1):17–22.Gomez Barreto D., De la Torre C., Alvarez A. et al. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children. Allergologia et immunopatho­ logia. 1998;26(1):17–22.Esposito S. et al. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014;32(22):2546–2552.Esposito S. et al. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014;32(22):2546–2552.Esposito S. et al. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. Journal of translational medicine. 2019;17(1):284.Esposito S. et al. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. Journal of translational medicine. 2019;17(1):284.Esposito S. et al. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: a retrospective study. International journal of envi­ ronmental research and public health. 2019;16(6):1065.Esposito S. et al. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: a retrospective study. International journal of envi­ ronmental research and public health. 2019;16(6):1065.Razi C.H. et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. Journal of allergy and clinical immunol­ ogy. 2010;126(4):763–769.Razi C.H. et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. Journal of allergy and clinical immunol­ ogy. 2010;126(4):763–769.Han R.F. et al. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom. Eur Rev Med Pharmacol Sci. 2016;20(10):2151–2155.Han R.F. et al. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom. Eur Rev Med Pharmacol Sci. 2016;20(10):2151–2155.

The authors declare that there are no conflicts of interest present.